



Financial Tear Sheet

Corporate Profile

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia.

Stock Quote

SNSS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.61
Change (%)	▲ 0.05 (1.95%)
Volume	79,537
52 Week Low	\$2.50
Market Cap	\$56,235,489
Rolling EPS	-2.19
PE Ratio	N/A
Shares Outstanding	21,513,194

Data as of 07/24/17 1:55 p.m. ET

Stock Chart



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
07/24/17	Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights

Upcoming Events

Date	Title
07/27/17 2:00 p.m. ET	Q2 2017 Sunesis Pharmaceuticals, Inc. Earnings Conference Call

07/18/17 Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies

06/26/17 Sunesis Pharmaceuticals Added to Russell Microcap® Index

Analyst Ratings

1-Strong Buy 1


2-Buy 0

3-Hold 2

4-Underperform 0

5-Sell 0

Mean Recommendation: 2.3



SEC Filings

Filing Date	Form
07/12/17	4
07/12/17	SC TO-I/A
07/05/17	SC 13G
06/30/17	8-K

Investor and Media Inquiries:

Maeve Conneighton

Argot Partners
206.899.4940

Dan Swisher

Sunesis Pharmaceuticals, Inc.
650-266-3715

Board of Directors

Steve R. Carchedi Director

Steven B. Ketchum, Ph.D. Director

Dayton Misfeldt Director

Geoffrey M. Parker Director

Homer L. Pearce, Ph.D. Director

David C. Stump, M.D. Director

Management

Daniel N. Swisher, Jr. Chief Executive Officer and President

Judith A. Fox, Ph.D. Chief Scientific Officer

Parvinder S. Hyare Vice President, Global Oncology Operations

Gene Jamieson Vice President, Technical Operations

Linda Neuman, MD, MBA Vice President, Clinical Development

Daniel N. Swisher, Jr. Chief Executive Officer
and President

James W. Young, Chairman
Ph.D.

Jennifer A. Smith, Vice President, Biometrics
Ph.D.

Deborah Senior Vice President,
A. Thomas, Ph.D. Regulatory Affairs, Quality
Assurance, and Nonclinical
Development